EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD(r) Use During the COVID-19 Pandemic

Source :: Plus Company Updates. April 24, 2021
Publication Year :: 2021
Abstract: ROCKLAND: EMD SERONO has issued the following news release: EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the [...]

Subjects :: Merck KGaA
Pfizer Inc.
Multiple sclerosis -- Care and treatment
Viral antibodies -- Analysis
B cells -- Analysis
Vaccines -- Analysis
Antibodies -- Analysis
Pharmaceutical industry -- Analysis
General interest
News, opinion and commentary
American Academy of Neurology
Mavenclad (Medication)

Tools